IIIT Hyderabad conducts ABDM 2.0 southern region seminar, arranged by NHA
In a significant development for the pharmaceutical industry, Zydus Therapeutics has announced positive topline results from the EPICS-III Phase 2(b)/3 Trial of Saroglitazar Magnesium. The trial was conducted on patients with primary biliary cholangitis.
Dr. Dipak Desai, the head of the EPICS-III Phase 2/3 Trial, reported these promising results. Saroglitazar Magnesium, a drug developed by Zydus Therapeutics, showed positive results in the trial, indicating a potential success for the treatment of primary biliary cholangitis.
However, no further details about the nature or scope of these positive topline results have been provided as of yet.
Meanwhile, in the healthcare sector in India, there has been a notable partnership formed between Mahajan Imaging & Labs and Fortis La Femme. The partnership is focused on women and child healthcare and diagnosis in India, particularly in Tier 2 and Tier 3 cities, which are identified as the future growth areas for healthcare.
Interestingly, no prior facts about any partnerships or collaborations between Mahajan Imaging & Labs and Fortis La Femme have been provided. Similarly, no information was given about any previous collaborations between Novo Nordisk and Apollo Clinics.
This latest announcement from Zydus Therapeutics marks a significant step forward in the treatment of primary biliary cholangitis, a liver disease that affects women more frequently. As more details about the EPICS-III trial and the partnership between Mahajan Imaging & Labs and Fortis La Femme emerge, we will keep you updated.
